Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP11B2 | P19099 | 20/20 | 0.74 |
| ▸ | CYP11B1 | P15538 | 16/20 | 0.74 |
| ▸ | CYP19A1 | P11511 | 2/20 | 0.53 |
| ▸ | ADRA2B | P18089 | 2/20 | 0.53 |
| ▸ | ADRB1 | P08588 | 1/20 | 0.53 |
| ▸ | ADRA2A | P08913 | 1/20 | 0.53 |
| ▸ | ADRA2C | P18825 | 1/20 | 0.53 |
| ▸ | HTR2C | P28335 | 1/20 | 0.53 |
| ▸ | HTR2B | P41595 | 1/20 | 0.53 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17896585 | 0.85 | CYP11B2 (0.76) | CYP11B2CYP11B1CYP19A1ADRA2BADRB1 | |
| SCHEMBL20337639 | 0.85 | CYP11B2 (0.75) | CYP11B2CYP11B1CYP19A1ADRA2BADRB1 | |
| SCHEMBL20337618 | 0.85 | CYP11B2 (1.00) | CYP11B2CYP11B1CYP19A1ADRA2BADRB1 | |
| SCHEMBL31411937 | 0.85 | CYP11B2 (0.75) | CYP11B2CYP11B1CYP19A1ADRA2BADRB1 | |
| SCHEMBL20337711 | 0.84 | CYP11B2 (0.77) | CYP11B2CYP11B1CYP19A1ADRA2BADRB1 | |
| SCHEMBL20337633 | 0.82 | CYP11B2 (0.65) | CYP11B2CYP11B1CYP19A1ADRA2BADRB1 | |
| SCHEMBL20337690 | 0.82 | CYP11B2 (0.77) | CYP11B2CYP11B1 | |
| SCHEMBL17678354 | 0.81 | CYP11B2 (0.58) | CYP11B2CYP11B1CYP19A1ADRA2BADRB1 | |
| SCHEMBL20338349 | 0.80 | CYP11B2 (1.00) | CYP11B2CYP11B1 | |
| SCHEMBL20337659 | 0.79 | CYP11B2 (1.00) | CYP11B2CYP11B1CYP19A1ADRA2B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20180186773-A1 | METALLOENZYME INHIBITOR COMPOUNDS | CORXEL PHARMACEUTICALS HONG KONG LIMITED (HK) | 2018-07-05 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180186773-A1 | METALLOENZYME INHIBITOR COMPOUNDS | SOD1, RNASE1, FECH | CYP11B2 405/4885CYP11B1 370/4885CYP19A1 1309/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.